GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » Enterprise Value

Revive Therapeutics (XCNQ:RVV) Enterprise Value : C$6.62 Mil (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Revive Therapeutics's Enterprise Value is C$6.62 Mil. Revive Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.15 Mil. Therefore, Revive Therapeutics's EV-to-EBIT ratio for today is -5.76.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Revive Therapeutics's Enterprise Value is C$6.62 Mil. Revive Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.15 Mil. Therefore, Revive Therapeutics's EV-to-EBITDA ratio for today is -5.76.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Revive Therapeutics's Enterprise Value is C$6.62 Mil. Revive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil. Therefore, Revive Therapeutics's EV-to-Revenue ratio for today is .


Revive Therapeutics Enterprise Value Historical Data

The historical data trend for Revive Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Enterprise Value Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.77 56.95 171.41 144.27 14.23

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.06 36.93 14.23 12.90 10.20

Competitive Comparison of Revive Therapeutics's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Enterprise Value falls into.



Revive Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Revive Therapeutics's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as

Revive Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (XCNQ:RVV) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Revive Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6.617/-1.148
=-5.76

Revive Therapeutics's current Enterprise Value is C$6.62 Mil.
Revive Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Revive Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=6.617/-1.148
=-5.76

Revive Therapeutics's current Enterprise Value is C$6.62 Mil.
Revive Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Revive Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.617/0
=

Revive Therapeutics's current Enterprise Value is C$6.62 Mil.
Revive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (XCNQ:RVV) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Executives
Michael Frank Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines